Filing identity and reporting period
Important issuer mismatch: The supplied filing is Eliem Therapeutics, Inc.’s Form 10-K, not a filing for Climb Bio, Inc. It covers the fiscal year ended December 31, 2021; it does not provide standalone fourth-quarter results.
Eliem is a clinical-stage biotechnology company developing treatments for chronic pain, depression and epilepsy. It had no approved products and generated no product revenue.
Financial and operating highlights
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense, net of U.K. tax credits | $23.3 million | $9.3 million |
| General and administrative expense | $12.4 million | $2.4 million |
| Total operating expenses | $35.7 million | $20.9 million |
| Net loss | $47.5 million | $20.7 million |
| Net cash used in operating activities | $36.1 million | $14.1 million |
| Cash, cash equivalents and marketable securities at year-end | $161.4 million | $20.5 million |
At December 31, 2021, cash was $46.9 million and marketable securities were $114.5 million. Current assets were $148.3 million and current liabilities were $6.0 million. The filing reports no material debt balance; total liabilities were $6.0 million. Profit margins are not meaningful because the company had no revenue.
Net loss per share attributable to common stockholders was $4.24 in 2021 versus $10.49 in 2020; the comparison is affected by the IPO and the conversion of preferred stock into common shares.
Changes from the prior year and unusual items
- Net loss increased by $26.8 million. Operating expenses rose $14.7 million, reflecting greater clinical and preclinical activity, higher staffing and public-company costs. The 2021 loss also included an $11.7 million noncash charge from remeasuring a preferred-stock tranche liability.
- R&D costs increased primarily with ETX-810 and ETX-155 clinical work and preclinical programs; higher U.K. refundable R&D tax credits partially offset the increase.
- Cash and securities increased after financing activity. Eliem received $83.1 million in net IPO proceeds and $93.9 million in net proceeds from preferred-stock issuances in 2021. Preferred shares converted to common stock when the IPO closed in August.
- 2020 included a $9.2 million acquired in-process R&D charge related to the Athenen acquisition; there was no comparable charge in 2021.
Outlook, management commentary and risks
- Management estimated year-end resources would fund operations through late 2023, based on its operating plan and assumptions. It expects to need additional capital to complete development and commercialize any approved products.
- ETX-810 was in Phase 2a trials for diabetic peripheral neuropathic pain and lumbosacral radicular pain. Management expected topline results in the first half and second half of 2022, respectively.
- ETX-155 was in a Phase 1b photosensitive-epilepsy trial, with interim data expected in the first half of 2022. Phase 2a trials for major depressive disorder and perimenopausal depression were planned for the first half of 2022, subject to FDA clearance, with topline data expected in the second half of 2023.
- Two preclinical programs were advancing; management expected to begin IND-enabling studies for its Kv7.2/3 program in 2022.
- Key risks include clinical and regulatory uncertainty, potential delays or failure of trials, reliance on third-party research and manufacturing providers, competition, intellectual-property challenges and dependence on future financing. COVID-19 had caused some supply and vendor delays, but management said it had not materially affected operations to date.
- Management reported material weaknesses in financial-reporting controls, including insufficient accounting resources, inadequate formal accounting controls and deficiencies in IT general controls. Disclosure controls were deemed ineffective at year-end. Remediation was underway but not yet established as effective.
- No material legal proceedings were reported. The independent auditor issued an unqualified opinion on the financial statements.
Investor verification priorities
- Confirm the issuer: the source is Eliem Therapeutics, not Climb Bio.
- Review subsequent clinical-trial results and regulatory developments against the stated timelines, including whether the ETX-155 IND received FDA clearance.
- Assess cash burn, marketable-security liquidity and financing needs against management’s late-2023 runway estimate.
- Track remediation and testing of the disclosed material weaknesses in internal controls.
- Review the assumptions behind the noncash $11.7 million tranche-liability remeasurement and the accounting for U.K. R&D tax credits.